Key Press Releases

Q-Sera enters exclusive agreement with Terumo Corporation for RAPClot® rapid serum blood collection tube technology in Japan

November 29, 2021

Q-Sera Pty Ltd, an Australian venture-backed company, today announced a partnership with Terumo Corporation, the leading Japanese medical device company, which will see its patent protected RAPClot® rapid serum tube technology manufactured and used in Japan.

RAPClot® serum tubes (evacuated blood collection tubes) produce high quality serum in less than five minutes, reducing the turnaround time from sample collection to serum analysis compared with current technologies. RAPClot® is also effective in producing high quality serum from blood samples that contain anti-coagulants such as heparin. Up to 10 percent of hospital emergency department admissions are patients on anti-coagulant therapies and current blood collection tubes cannot efficiently clot their blood, resulting in a failure to clot or formation of fibrin strands which interfere with analysers. The ability of RAPClot® tubes to generate high quality serum in less than 5 minutes and to clot anti-coagulated blood samples represents a substantial step forward in patient diagnosis.

In hospital and community settings, as well as acute situations such as hospital emergency departments where speed matters, blood tests are commonly used to assist the accurate diagnosis of medical problems ranging from heart attacks to diabetes. A delay in test results means a delay in diagnosis and the right care for very sick patients. Having access to a technology that universally clots all blood samples within five minutes will contribute to improved patient outcomes and reduced healthcare costs.

Under the terms of the partnership, Terumo Corporation has been granted the exclusive rights to manufacture and market Q-Sera’s rapid serum tube technology in Japan. Q-Sera will also supply Terumo Corporation with the recombinant protein RAPClot®.

Michael Grant, CEO of Q-Sera, said, “Q-Sera is pleased to be partnering with Terumo Corporation for the Japanese market. Terumo Corporation is a leading global medical device company and has a history of innovation in the field of blood collection tubes and together we look forward to bringing this next-generation tube technology to the market to benefit Japanese patients”.

Tsuyoshi Tomita, Senior Executive Officer of Terumo said, “RAPClot® has the potential to dramatically improve issues such as coagulation time, heparinised blood, and fibrin strands in tests with serum. It will be a great pleasure for Terumo to be able to partner with Q-Sera to improve the accuracy of diagnosis using blood collection tubes.”.

Q-Sera is actively seeking partners for other regions.

Download PDF

Q-Sera Pty Ltd and JHL Biotech, Inc. announce a strategic collaboration (Note: JHL Biotech is now Bora Biologics Co., Ltd)

May 21, 2020, Melbourne, Australia

Q-Sera Pty Ltd is pleased to announce a collaboration with JHL Biotech, Inc. (Taiwan) to produce high yielding recombinant ecarin for commercial scale production of RAPClot® Rapid Serum tubes. Q-Sera has developed a superior serum/blood clotting tube, RAPClot® Rapid Serum tube, for widespread use in hospitals and pathology labs.

The companies have been collaborating under JHL’s partnering program in which it works with companies on products with disruptive potential such as Q-Sera’s RAPClot® Rapid Serum tube. Michael Grant, CEO of Q-Sera, said, “JHL Biotech’s proprietary technology has already been able to demonstrate that we can achieve high yield and low cost production of recombinant ecarin for use in our blood clotting tubes. This is potentially disruptive as Q-Sera seeks to provide a superior replacement for current serum and plasma tubes with the RAPClot® Rapid Serum tube.

Read more

Q-Sera’s innovative blood clotting technology granted patent in US

August 19, 2019

Medical device company Q-Sera Pty Ltd today announces that it has received a Notice of Allowance from the United States Patent & Trademark Office for the foundation patent of its innovative blood clotting technology for use in blood collection tubes.

Q-Sera’s technology now has patent protection for use in blood collection tubes in the United States, Europe, Japan, China, Mexico, Russia, Canada, South Africa and Australia. Q-Sera is progressing additional patents to cover novel formulations and expanded uses for its unique actives, extending the commercial opportunities.

Read more

International Expert in Blood Collection Tubes joins Q-Sera

October 2, 2018

Q-Sera Pty Ltd (Q-Sera) is pleased to announce the addition of international consultant and expert in the field of blood collection tubes, Franz E. Kirchmeir to our growing company to further R&D efforts and assist in the commercialization of the RAPClot® technology.

Franz was previously the Director of Business Development at Greiner Bio-One Preanalytics at their global headquarters in Austria. He brings 20 years’ experience in the pre-analytical business sector including blood collection tubes, as well as extensive knowledge in R&D management, business development and strategic management. Q-Sera is pleased to welcome Franz to the team to help bring our technology into international markets.

Read more

Q-Sera’s innovative blood clotting technology presented at leading international scientific conference

October 23, 2017

A poster presentation on Q-Sera’s recombinant prothrombin activator RAPClot® technology for blood collection tubes was made at the 23rd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC Worldlab) in Durban, South Africa.

Read more


Zhao et al, Rapid serum tube technology overcomes problems associated with use of anticoagulants. BioMedica 2019;29(3):1-17.
Zhao et al, Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high quality serum from normal samples. Clin Chem Lab Med 2019 Mar 26; 57(4):483-497.
Johnson et al, Progress Curve Analysis of the one stage chromogenic assay for ecarin, Anal Biochem 2020, 608: 1-7
Zhao et al, Potential application of recombinant snake prothrombin activator ecarin in blood diagnostics. Biomolecules 2022, 12(11): 1704;